0 528

Cited 10 times in

Comparison of the intraocular pressure-lowering effect and safety of brimonidine/timolol fixed combination and 0.5% timolol in normal-tension glaucoma patients.

Authors
 Joon Mo Kim  ;  Tae-Woo Kim  ;  Chan Yun Kim  ;  Hwang Ki Kim  ;  Ki Ho Park 
Citation
 JAPANESE JOURNAL OF OPHTHALMOLOGY, Vol.60(1) : 20-26, 2016 
Journal Title
JAPANESE JOURNAL OF OPHTHALMOLOGY
ISSN
 0021-5155 
Issue Date
2016
MeSH
Administration, Topical ; Aged ; Antihypertensive Agents/adverse effects ; Antihypertensive Agents/therapeutic use* ; Brimonidine Tartrate/adverse effects ; Brimonidine Tartrate/therapeutic use* ; Corneal Pachymetry ; Drug Combinations ; Female ; Humans ; Intraocular Pressure/drug effects* ; Low Tension Glaucoma/drug therapy* ; Low Tension Glaucoma/physiopathology ; Male ; Middle Aged ; Ophthalmic Solutions ; Prospective Studies ; Timolol/adverse effects ; Timolol/therapeutic use* ; Tonometry, Ocular
Keywords
0.5 % timolol ; Brimonidine/timolol fixed combination ; Drug efficacy ; Normal-tension glaucoma
Abstract
PURPOSE: To compare the therapeutic efficacy and safety of brimonidine/timolol fixed-combination (BTFC) and 0.5% timolol ophthalmic solution in normal-tension glaucoma (NTG) patients.
METHODS: This was a multi-institution, randomized, active-controlled, open-label, parallel-group study. After a full ophthalmic and glaucoma examination, a total of 110 NTG patients--55 undergoing therapy with BTFC and 55 0.5%, with timolol--participated in this study. Among them, 1 failed to meet the inclusion/exclusion criteria, 10 revoked their consent to participate in the study, 3 had adverse reactions, and 1 had a drug adherence rate of less than 70%. Ultimately, a total of 95 patients--48 in the BTFC group and 47 in the 0.5% timolol group--completed the study. The study visits took place at baseline and at 4 and 12 weeks. Diurnal IOP was measured at 9 a.m., 11 a.m., and 5 p.m. during the baseline visit and the visit at 12 weeks after eye-drop instillation. At each follow-up visit, compliance was assessed. Throughout the study, all adverse events were recorded and monitored by the investigators.
RESULTS: The average difference in IOP change measured at 11 a.m. 12 weeks after administration between the two groups was 2.10 ± 2.59 mmHg. The BTFC group had a better IOP-lowering effect at all time points than did the 0.5% timolol group. The ratio of patients whose average IOP had decreased by >20% after 4 and 12 weeks was 50 and 56% in the BTFC group, respectively, whereas it was 29.41 and 23.53% in the 0.5% timolol group, respectively (p = 0.034, <0.001).
CONCLUSIONS: BTFC has a superior IOP-lowering effect than 0.5% timolol in NTG patients.
Full Text
http://link.springer.com/article/10.1007/s10384-015-0420-2
DOI
10.1007/s10384-015-0420-2
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Ophthalmology (안과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Chan Yun(김찬윤) ORCID logo https://orcid.org/0000-0002-8373-9999
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/147084
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links